## **Oncology Dermatology Medication Enrollment Form**

## **Medications A-O**

(Braftovi, Cotellic, Erivedge, Keytruda, Mekinist, Mektovi, Odomzo, Opdivo, Opdualag)



Fax Referral To: 1-877-232-5455 Address: 500 Ala Moana Blvd., Bldg 1 Honolulu, HI 96813 Phone: 1-808-254-2727 NCPDP: 1203417

	Six Sir	mple Steps to Sub	omitting a Referral				
PATIENT INFOR	MATION (Complete or includ	e demographic sheet)					
_	ON (Complete or include dem						
· · · · · · · · · · · · · · · · · · ·		DOB: Gender: Male		Female			
Address:		City	, State, ZIP Code:				
Preferred Contact Methods: O Phone (to primary # provided below) O Text (to cell # provided below) O Email (to email provided below)							
			re, you are consenting to receive automated calls, emails ar standard data rates apply. Message frequency varies. If una				
text or email, Specialty Pharmacy will attempt to contact by phone.							
Primary Phone: Alternate Phone: Email: Last Four of SSN: Primary Language:							
Email:	mail: Primary Language: Parent/Caregiver/Legal Guardian Name (Last, First): Relationship Patient:						
		i):	Relationship Patient:				
2 PRESCRIBER IN			<b></b>				
Prescriber's Name:	DEA #:	State License #:oup or Hospital:					
NPI #:	DEA #: GI	roup or Hospital:	tu State ZID Code:				
Phono:	Eav:	City, State, ZIP Code: Contact's Phone: Contact Person: Contact's Phone:					
INCLIDANCE INC	OPMATION Places for an	Contact Ferson	d insurance cards with this form, if available (from	at and back)			
			Ship to: Patient Office Other:	•			
Diagnosis (ICD-10):							
Code: Descr	ription		Code: Description				
Code: Descr	ription		Code: Description				
<b>Patient Clinical Info</b>	rmation: Allergies:		Weight:lb/kg Height:in/cm				
5 PRESCRIPTION	INFORMATION						
<b>DRUG NAME</b>	STRENGTH		SIG/DIRECTIONS QUA	ANTITY/REFILLS			
_	☐ 50 mg		aily in combination with Mektovi 45 mg PO twice daily				
☐ Braftovi	75 mg		aily in combination with Erbitux	Quantity:			
		Other:		Refills:			
☐ Cotellic	20 mg	3 tablets PO once daily days 1-21, off 7 days. Recycle every 28 days.  Other:  Quantity: Refills:					
	450	☐ 1 capsule PO once daily Quantity:					
☐ Erivedge	150 mg	Other: Refills:					
☐ Keytruda	100 mg/4 mL	☐ 200 mg IV every 3 weeks ☐ 400 mg IV every 6 weeks ☐ Quantity:					
Mekinist	☐ 2 mg ☐ 0.5 mg	☐ 1 tablet PO once daily Quantity: ☐ Other: Refills:					
☐ Mektovi	15 mg	45 mg PO twice daily in combination with Braftovi 450 mg PO once daily Quantity: Refills:					
Odomzo	200 mg	☐ 1 capsule PO once daily Quantity: Refills:					
Opdivo	☐ 40 mg/4 mL ☐ 100 mg/10 mL ☐ 240 mg/24 mL	240 mg IV every two weeks 480 mg IV every four weeks Quantity:					
Opdualag (nivolumab and relatimab-rmbw)	240 mg-80 mg/20 mL	☐ 480 mg nivolumab and 160 mg relatlimab IV every 4 weeks Quantity: Refills:					
Patient is interested in patient support programs STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as needed for administration PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)							
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution /  May Substitute / Product Selection Permitted /							
DAW / May Not Substitute  DAW / May Not Substitute  Substitution Permissible							
	ıre:	Date:	Prescriber's Signature:	Date:			
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescription							

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

## **Oncology Dermatology Medication Enrollment Form**

## **Medications P-Z**

(Poteligeo, Tafinlar, Tecentriq, Yervoy, Zelboraf, Zolinza)

	Ple	ase Complete Patie <u>nt a</u>	nd Prescriber Information	
Patient Nam	e:	Patient DOB:	tient DOB:Patient Phone Number_	
Prescriber N	ame:		_ Prescriber Phone:	
5 PRESCRIP	TION INFORMATIO	N		
DRUG NAME	STRENGTH	SIG	/DIRECTIONS	QUANTITY/REFILLS
Poteligeo	20 mg/5 mL	1 mg/kg IV Days 1, 8, 15, 22 x 1 cycle 1 mg/kg IV every 2 weeks Other:		Quantity: Refills:
Tafinlar	☐ 50 mg ☐ 75 mg	2 capsules PO twice daily Other:	Quantity: Refills:	
Tecentriq	840 mg/14 mL	840 mg IV every 2 weeks Other:	Quantity: Refills:	
☐ Yervoy	☐ 50 mg/10 mL ☐ 200 mg/40 mL	3 mg/kg IV every 3 weeks x 4 doses 10 mg/kg IV every 3 weeks x 4 doses 10 mg/kg IV every 12 weeks Other:		Quantity: Refills:
Zelboraf	240 mg	4 tablets PO twice daily Other:		Quantity: Refills:
Zolinza	100 mg	4 capsules PO once daily Other:		Quantity: Refills:
PRESCRIPTIO	NS DRUG NAM	ME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
Rx 1	☐ Other:	Othe	r:	Quantity: Refills:
Rx 2	Other:	Othe	r:	Quantity: Refills:
Rx 3	Ondansetron Promethazine	☐ Othe	r:	Quantity: Refills:
Patient is interes	sted in patient support progra	ms STAMP SIGNATURE	NOT ALLOWED Ancillary supplies and kits	provided as needed for administration
	6 PRESCRIBER	SIGNATURE REQUIRED (	STAMP SIGNATURE NOT A	LLOWED)
Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Su AW / May Not Substitute Prescriber's Signature:			May Substitute / Product Selection Permitte Substitution Permissible  Prescriber's Signature:	
			ATTN: New York and Iowa pro	
	<u> </u>		Arminon forkuna ionapie	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.